NasdaqCM:OVIDBiotechs
Ovid Therapeutics (OVID): Evaluating Valuation After Positive Phase 1 Trial Results and $175 Million Financing
Ovid Therapeutics has grabbed investor attention after unveiling encouraging Phase 1 results for its next-generation epilepsy drug, OV329. In addition to the promising data, the company secured $175 million in new financing, extending its cash runway.
See our latest analysis for Ovid Therapeutics.
After surging on the back of positive Phase 1 data and a major private financing announcement, Ovid Therapeutics has seen renewed bullishness, with momentum building over the short term. While the...